Key result
Direct oral anticoagulants effectively reduce recurrent venous thromboembolism in cancer patients compared to low-molecular-weight heparins, but increase the risk of clinically relevant non-major gastrointestinal bleeding.
Why the study?
Does direct oral anticoagulants reduce recurrent VTE in cancer patients with venous thromboembolic disease?
Does direct oral anticoagulants reduce recurrent VTE in cancer patients with venous thromboembolic disease?
DOACs are an effective and safe alternative to LMWH for treating VTE in cancer patients, though caution is needed in those with gastrointestinal or urothelial cancers due to higher bleeding risks.
Answers are grounded in this paper and cite their sources.
Level 5 vascular evidence remains hypothesis-generating; larger trials needed before any practice consideration.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sánchez et al. (2021) conducted a review in Venous thromboembolic disease associated with cancer. Direct oral anticoagulants (DOACs) vs. Low-molecular-weight heparins (LMWH) was evaluated on Recurrent venous thromboembolism and major bleeding. Direct oral anticoagulants effectively reduce recurrent venous thromboembolism in cancer patients compared to low-molecular-weight heparins, but increase the risk of clinically relevant non-major gastrointestinal bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: